Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Investing
2 of the best buys on the ASX: QBE Insurance Group Ltd and Cochlear Limited
⏸️ Investing
The Race to $100: A new contender
⏸️ Investing
The ridiculously simple way to grow rich and smash the ASX200
⏸️ Investing
Which 4 stocks will benefit from a weaker Australian dollar?
⏸️ Investing
Why these 5 ASX stocks are surging higher at noon
⏸️ Investing
Why Cochlear Limited shares are skyrocketing today
⏸️ Investing
Ramsay Health Care Limited vs Cochlear Limited: which health care stock should you buy?
⏸️ Investing
3 reasons to buy Cochlear Limited during a market meltdown
⏸️ Investing
Ignore Greece, keep calm and carry on investing
⏸️ Investing
9 blue-chip companies to buy for a lower Australian dollar
⏸️ Investing
Morning market movers: 11 stocks to watch
⏸️ Investing
Is Cochlear Limited a better buy than CSL Limited?
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
